Novel molecular biomarkers of cancer therapy‐induced cardiotoxicity in adult population: a scoping review
Abstract Aim Cancer treatments are associated with cardiotoxic events that predispose to cardiac pathology and compromise the survival of patients, making necessary the identification of new molecular biomarkers to detect cardiotoxicity. This scoping review aims to identify the available evidence on...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13735 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540344249483264 |
|---|---|
| author | Irene Cartas‐Espinel Marcelino Telechea‐Fernández Carlos Manterola Delgado Andrés Ávila Barrera Nicolás Saavedra Cuevas Angela L. Riffo‐Campos |
| author_facet | Irene Cartas‐Espinel Marcelino Telechea‐Fernández Carlos Manterola Delgado Andrés Ávila Barrera Nicolás Saavedra Cuevas Angela L. Riffo‐Campos |
| author_sort | Irene Cartas‐Espinel |
| collection | DOAJ |
| description | Abstract Aim Cancer treatments are associated with cardiotoxic events that predispose to cardiac pathology and compromise the survival of patients, making necessary the identification of new molecular biomarkers to detect cardiotoxicity. This scoping review aims to identify the available evidence on novel molecular biomarkers associated with cardiotoxicity in the adult population undergoing cancer therapy. Methods and results The databases Medline, Web of Science, Scopus, and Embase were screened for the identification of published studies until 23 August 2020, searching for novel molecular biomarkers reported in cancer therapy‐related cardiac dysfunction in adult patients. A total of 42 studies that met the eligibility criteria were included. Fourteen studies reported 44 new protein biomarkers, 18 studies reported 57 new single nucleotide polymorphism biomarkers, and 11 studies reported 171 new gene expression profiles associated with cardiotoxicity. Data were extracted for 272 novel molecular biomarkers reported and evaluated in 7084 cancer patients, of which only 13 were identified in more than one study (MPO, sST2, GDF‐15, TGF‐B1, rs1056892, rs1883112, rs4673, rs13058338, rs1695, miR‐1, miR‐25‐3p, miR‐34a‐5p, and miR‐423‐5p), showing values for area under the curve > 0.73 (range 0.74–0.85), odds ratio 0.26–7.17, and hazard ratio 1.28–1.80. Conclusions Multiple studies presented a significant number of novel molecular biomarkers as promising predictors for risk assessment of cardiac dysfunction related to cancer therapy, but the characteristics of the studies carried out and the determinations applied do not allow suggesting the clinical use of these molecular biomarkers in the assessment of cancer therapy‐induced cardiotoxicity. |
| format | Article |
| id | doaj-art-b4be8c664c484a3a8b80bd380794b5b0 |
| institution | Kabale University |
| issn | 2055-5822 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj-art-b4be8c664c484a3a8b80bd380794b5b02025-02-05T05:22:10ZengWileyESC Heart Failure2055-58222022-06-01931651166510.1002/ehf2.13735Novel molecular biomarkers of cancer therapy‐induced cardiotoxicity in adult population: a scoping reviewIrene Cartas‐Espinel0Marcelino Telechea‐Fernández1Carlos Manterola Delgado2Andrés Ávila Barrera3Nicolás Saavedra Cuevas4Angela L. Riffo‐Campos5Programa de Doctorado en Ciencias mención Biología Celular y Molecular Aplicada Universidad de La Frontera Temuco ChileDepartamento de Fisiología Universidad de Valencia Valencia SpainDepartamento de Cirugía Universidad de La Frontera Temuco ChileCentro de Excelencia de Modelación y Computación Científica Universidad de La Frontera Temuco ChileDepartamento de Ciencias Básicas Universidad de La Frontera Temuco ChilePrograma de Doctorado en Ciencias Médicas Universidad de La Frontera Temuco ChileAbstract Aim Cancer treatments are associated with cardiotoxic events that predispose to cardiac pathology and compromise the survival of patients, making necessary the identification of new molecular biomarkers to detect cardiotoxicity. This scoping review aims to identify the available evidence on novel molecular biomarkers associated with cardiotoxicity in the adult population undergoing cancer therapy. Methods and results The databases Medline, Web of Science, Scopus, and Embase were screened for the identification of published studies until 23 August 2020, searching for novel molecular biomarkers reported in cancer therapy‐related cardiac dysfunction in adult patients. A total of 42 studies that met the eligibility criteria were included. Fourteen studies reported 44 new protein biomarkers, 18 studies reported 57 new single nucleotide polymorphism biomarkers, and 11 studies reported 171 new gene expression profiles associated with cardiotoxicity. Data were extracted for 272 novel molecular biomarkers reported and evaluated in 7084 cancer patients, of which only 13 were identified in more than one study (MPO, sST2, GDF‐15, TGF‐B1, rs1056892, rs1883112, rs4673, rs13058338, rs1695, miR‐1, miR‐25‐3p, miR‐34a‐5p, and miR‐423‐5p), showing values for area under the curve > 0.73 (range 0.74–0.85), odds ratio 0.26–7.17, and hazard ratio 1.28–1.80. Conclusions Multiple studies presented a significant number of novel molecular biomarkers as promising predictors for risk assessment of cardiac dysfunction related to cancer therapy, but the characteristics of the studies carried out and the determinations applied do not allow suggesting the clinical use of these molecular biomarkers in the assessment of cancer therapy‐induced cardiotoxicity.https://doi.org/10.1002/ehf2.13735CardiotoxicityMolecular biomarkersLVEFCTRCDCancer therapyCardio‐oncology/onco‐cardiology |
| spellingShingle | Irene Cartas‐Espinel Marcelino Telechea‐Fernández Carlos Manterola Delgado Andrés Ávila Barrera Nicolás Saavedra Cuevas Angela L. Riffo‐Campos Novel molecular biomarkers of cancer therapy‐induced cardiotoxicity in adult population: a scoping review ESC Heart Failure Cardiotoxicity Molecular biomarkers LVEF CTRCD Cancer therapy Cardio‐oncology/onco‐cardiology |
| title | Novel molecular biomarkers of cancer therapy‐induced cardiotoxicity in adult population: a scoping review |
| title_full | Novel molecular biomarkers of cancer therapy‐induced cardiotoxicity in adult population: a scoping review |
| title_fullStr | Novel molecular biomarkers of cancer therapy‐induced cardiotoxicity in adult population: a scoping review |
| title_full_unstemmed | Novel molecular biomarkers of cancer therapy‐induced cardiotoxicity in adult population: a scoping review |
| title_short | Novel molecular biomarkers of cancer therapy‐induced cardiotoxicity in adult population: a scoping review |
| title_sort | novel molecular biomarkers of cancer therapy induced cardiotoxicity in adult population a scoping review |
| topic | Cardiotoxicity Molecular biomarkers LVEF CTRCD Cancer therapy Cardio‐oncology/onco‐cardiology |
| url | https://doi.org/10.1002/ehf2.13735 |
| work_keys_str_mv | AT irenecartasespinel novelmolecularbiomarkersofcancertherapyinducedcardiotoxicityinadultpopulationascopingreview AT marcelinotelecheafernandez novelmolecularbiomarkersofcancertherapyinducedcardiotoxicityinadultpopulationascopingreview AT carlosmanteroladelgado novelmolecularbiomarkersofcancertherapyinducedcardiotoxicityinadultpopulationascopingreview AT andresavilabarrera novelmolecularbiomarkersofcancertherapyinducedcardiotoxicityinadultpopulationascopingreview AT nicolassaavedracuevas novelmolecularbiomarkersofcancertherapyinducedcardiotoxicityinadultpopulationascopingreview AT angelalriffocampos novelmolecularbiomarkersofcancertherapyinducedcardiotoxicityinadultpopulationascopingreview |